Stocktoria
ANAVEX LIFE SCIENCES CORP. AVXL
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2006-04-13
ANAVEX LIFE SCIENCES CORP. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $37.6M | $41.8M | $43.7M | $37.9M | $33.0M |
| SG&A expense | $13.8M | $11.0M | $12.0M | — | — |
| Operating income | -$51.4M | -$52.9M | -$55.8M | -$51.0M | -$42.0M |
| Net income | -$46.4M | -$43.0M | -$47.5M | -$48.0M | -$37.9M |
| EPS (diluted) | $-0.54 | $-0.52 | $-0.60 | $-0.62 | $-0.54 |
| Operating cash flow | -$39.0M | -$30.8M | -$27.8M | -$24.2M | -$30.4M |
| Cash & equivalents | $102.6M | $132.2M | $151.0M | $149.2M | $152.1M |
| Total assets | $103.8M | $135.6M | $154.4M | $152.7M | $161.6M |
| Total liabilities | $8.9M | $15.3M | $12.5M | $10.2M | $10.8M |
| Shareholders' equity | $94.9M | $120.3M | $141.9M | $142.5M | $150.8M |
Source: SEC EDGAR filings · CIK 0001314052 · as of 2025-09-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.